lunedì, 4 maggio 2026

Notizie AIOM – anno XV

ASCO Releases Its State of Cancer Care in America: 2017 Report

March 22, 2017 - In a press briefing today on Capitol Hill, ASCO presented its fourth annual State of Cancer Care in America: 2017 report, which found that although the cancer care delivery system in the United States is undergoing profound changes to better meet the needs ...
Leggi tutto

Binimetinib Application for NRAS-Mutant Melanoma Withdrawn

March 20, 2017 - Array BioPharma has withdrawn its new drug application (NDA) for the MEK inhibitor binimetinib as a treatment for patients with NRAS-mutant advanced melanoma, based on feedback from the FDA during a preplanned review meeting. The application for binimetinib ...
Leggi tutto

Pembrolizumab Recommended for EU Approval in Hodgkin Lymphoma

March 24, 2017 - The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have progressed following autologous stem ...
Leggi tutto

Nivolumab Recommended for EU Approval in Head and Neck Cancer

March 24, 2017 - The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck (SCCHN) following progression on platinum-based therapy, according to ...
Leggi tutto

24 marzo 2017 – SCOPE JA Stakeholder Event 20-21 Marzo 2017 a Londra

24 marzo 2017 – Disposizioni in materia di medicinali per terapie avanzate preparati su base non ripetitiva

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial

Stomatitis is a class e ect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and interruptions of everolimus. Anecdotal use ...
Leggi tutto

Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: Results from a population-based analysis of 10,794 cases

Currently, the 5-year survival rate for rectal cancer remains at <60%. The identification of potentially modifiable prognostic factors would be of considerable public health importance. A few studies have suggested associations between smoking and survival in rectal ...
Leggi tutto

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)

Treating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies show that statins exert additive effects with agents, such as cisplatin, to impair tumor growth, and observational studies suggest that statins combined with anticancer therapies ...
Leggi tutto

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

To determine the long-term prognosis in each phenotypic subset of breast cancer related to residual cancer burden (RCB) after neoadjuvant chemotherapy alone, or with concurrent human epidermal growth factor receptor 2 (HER2)-targeted treatment. We conducted a pathologic ...
Leggi tutto